Basel-based pharmaceutical giant Roche received European Union approval on Monday to market Susvimo, a treatment for neovascular age-related macular degeneration (nAMD), an advanced eye condition that can lead to severe vision loss.
The drug is administered through a small implant called Contivue, which is inserted once into the eye and continuously releases medication over time. Patients require only two refills per year, a significant reduction from the standard regimen of monthly intraocular injections currently used to treat the disease.
Susvimo was previously approved in the United States, Switzerland, and Thailand.
The approval marks another competitive development in the ophthalmology market, where Bayer remains a key rival in wet AMD therapies.
